S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
NASDAQ:IMNN

Imunon (IMNN) Stock Price, News & Analysis

$0.71
+0.10 (+16.39%)
(As of 02/27/2024 ET)
Today's Range
$0.59
$0.72
50-Day Range
$0.49
$0.80
52-Week Range
$0.48
$1.63
Volume
146,842 shs
Average Volume
61,964 shs
Market Capitalization
$6.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Imunon MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,590.1% Upside
$12.00 Price Target
Short Interest
Bearish
2.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.60mentions of Imunon in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.23) to ($1.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.58 out of 5 stars


IMNN stock logo

About Imunon Stock (NASDAQ:IMNN)

Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

IMNN Stock Price History

IMNN Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Bicycle Therapeutics Ltd. ADR
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Imunon GAAP EPS of -$0.37 beats by $0.29
Imunon: Q3 Earnings Insights
Imunon Q3 Earnings Preview
Imunon's Earnings Outlook
See More Headlines
Receive IMNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/27/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMNN
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+1,590.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-35,900,000.00
Pretax Margin
-23,541.60%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$4.13 per share

Miscellaneous

Free Float
9,038,000
Market Cap
$6.67 million
Optionable
Not Optionable
Beta
1.69
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Michael H. Tardugno (Age 73)
    Executive Chairman
    Comp: $1.58M
  • Dr. Corinne M. Le Goff M.B.A. (Age 59)
    Pharm.D., CEO, President & Director
    Comp: $477.73k
  • Mr. Jeffrey W. Church CPA (Age 67)
    CFO, Executive VP & Corporate Secretary
    Comp: $548.92k
  • Dr. Khursheed Anwer M.B.A. (Age 64)
    Ph.D., Executive VP & Chief Scientific Officer
    Comp: $540.87k
  • Mr. Timothy J. Tumminello CPA (Age 66)
    Chief Accounting Officer & Controller
    Comp: $108.31k
  • Ms. Marianne M. Lambertson
    Vice President of Communications & Investor Relations
  • Dr. Sebastien Hazard M.D. (Age 52)
    Executive VP & Chief Medical Officer














IMNN Stock Analysis - Frequently Asked Questions

Should I buy or sell Imunon stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Imunon in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMNN shares.
View IMNN analyst ratings
or view top-rated stocks.

What is Imunon's stock price target for 2024?

1 Wall Street analysts have issued 12 month price objectives for Imunon's stock. Their IMNN share price targets range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 1,590.1% from the stock's current price.
View analysts price targets for IMNN
or view top-rated stocks among Wall Street analysts.

How have IMNN shares performed in 2024?

Imunon's stock was trading at $0.68 at the start of the year. Since then, IMNN shares have increased by 4.4% and is now trading at $0.71.
View the best growth stocks for 2024 here
.

When is Imunon's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our IMNN earnings forecast
.

Who are Imunon's major shareholders?

Imunon's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.54%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Imunon?

Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMNN) was last updated on 2/28/2024 by MarketBeat.com Staff